A PYMNTS Company

US: Drug makers make $3.25B deal for multiple sclerosis drug

By  |  February 6, 2013

In what is still subject to a federal antitrust review, the boards of directors for two drug manufacturers have agreed to transfer full rights to the production of multiple sclerosis drug Tysabri. Elan and Biogen Idec have restructured their 50-50 split of the profits of the drug in a deal that gives Biogen full rights to it, while Elan gets a $3.25 billion payment and 12 percent of Biogen’s royalties of the drug for the first 12 months of the new agreement.

 

Full Content: Motley Fool

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.